Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

Vaccine

Volumn 25, Issue 49, 2007, Pages 8326-8337

  Pellissier, James M ^a   Brisson, Marc ^b   Levin, Myron J ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Cost; Cost effectiveness; Herpes zoster; Herpes zoster vaccine; Oka Merck strain of VZV vaccine; Postherpetic neuralgia; Shingles; Shingles Prevention Study

Indexed keywords

LIVE VACCINE; VARICELLA ZOSTER VACCINE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DRUG EFFICACY; HEALTH CARE UTILIZATION; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORBIDITY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STATISTICAL ANALYSIS; UNITED STATES; VACCINATION;

AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY;

EID: 36049027992     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.09.066     Document Type: Article

References (40)

1. Gnann J.-W.J., and Whitley R. Clinical practice. Herpes zoster. N Engl J Med 347 5 (2002) 340-346
2. Burke B., Steele R., Beard O., Wood J., Cain T., and Marmer D. Immune response to varicella-zoster in the aged. Arch Intern Med 142 (1982) 291-293
3. Miller A. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 30 (1980) 582-587
4. Levin M.J., Smith J., Kaufhold R., Barber D., Hayward A.R., Chan C.Y., et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with high-dose VZV vaccine. J Infect Dis 188 (2003) 1336-1344
5. Brisson M., Edmunds W.J., Law B., Gay N.J., Walld R., Brownell M., et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 127 2 (Oct 2001) 305-314
6. Edmunds W.J., Brisson M., and Rose J.D. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 30 April (23-24) (2001) 3076-3090
7. Yawn B., Wollan P., Saint-Sauver J., Kurland M., Sy L.S., and Saddier P. Herpes zoster in the community. North American Primary Care Research Group Meeting. Tucson, AZ, USA, October 2006 (2006)
8. Haanpaa M., Laippala P., and Nurmikko T. Allodynia and pinprick hypesthesia in acute herpes zoster, and the development of postherpetic neuralgia. J Pain Symptom Manage 20 1 (2000) 50-58
9. Scott F.T., Leedham-Green M.E., Barrett-Muir W.Y., Hawrami K., Gallagher W.J., Johnson R., et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 70 Suppl. 1 (2003) S24-S30
10. Oxman M.N., Levin M.J., Johnson G.R., Schmader K., and Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 22 (2005) 2271-2284
11. Levin M.J., Murray M., Rotbart H.A., Zerbe G.O., White C.J., and Hayward A.R. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 166 August (2) (1992) 253-259
12. Levin M.J., Murray M., Zerbe G.O., White C.J., and Hayward A.R. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 170 September (3) (1994) 522-526
13. Trannoy E., Berger R., Hollander G., Bailleux F., Heimendinger P., Vuillier D., et al. Vaccinatin of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 18 (2000) 1700-1706
14. U.S. Census Bureau Population Division. Population Projections Branch for 2005-2015. November 2, 2000.
15. Arias E. United States life tables, 2002. National vital statistics reports; vol. 53, no. 6. Hyattsville, Maryland: National Center for Health Statistics, 2004.
16. US Department of Health Human Services Center for Disease Control. Compressed mortality file. Series 20 on CDC Wonder Database 1999-2002 (2005), US Department of Health Human Services Center for Disease Control
17. Insinga R.P., Itzler R.F., Pellissier J.M., Saddier P., and Nikas A.A. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 20 (2005) 748-753
18. Saddier P., Yawn B., Wollan P., Kurland M., Sy L.S., Pellissier J.M., et al. Herpes zoster epidemiology and associated health care use in Olmsted County, MN, USA. Presented at Pharmacoepidemiology and Therapeutic Risk Management 22nd International Conference. Lisbon, Portugal, August 2006 (2006)
19. Insinga R.P., Itzler R.F., and Pellissier J.M. The healthcare resource utilization and costs of acute/subacute herpes zoster. Pharmacoeconomics 25 2 (2007) 155-169
20. U.S. Department of Labor Bureau of Labor Statistics. Employer costs for employee compensation. March 2006.
21. Brisson M., Johnson R.W., Levin M.J., Oxman M.N., and Schmader K.E. Measuring herpes zoster and post-herpetic neuralgia associated burden of illness, health care utilization and costs in Canada. Can J Infect Dis Med Microbiol 17 6 (2006) 381
22. Oster G., Harding G., Dukes E., Edelsberg J., and Cleary P.D. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: Results from a population-based survey. J Pain 6 6 (2005) 356-363
23. Hornberger J., and Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 145 5 (2006) 317-325
24. Bala M., Wood L., Zarkin G.A., Norton E.C., Gafni A., and O'Brien B.J. Valuing outcomes in health care: A comparison of willingness-to-pay and quality-adjusted life years. J Clin Epidemiol 51 8 (1998) 667-676
25. Coplan P.M., Schmader K., Nikas A., Chan I.S.F., Choo P., Levin M.J., et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 5 6 (2004) 344-356
26. Rothberg M.B., Virapongse A., and Smith K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 44 (2007) 1280-1288
27. Davies L., Cossins L., Bowsher D., and Drummond M. The cost of treatment for post-herpetic neuralgia in the UK. Pharmacoeconomics 6 2 (1994) 142-148
28. Dworkin R.H., White R., O'Connor A.B., Baser O., and Hawkins K. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc 55 8 (2007) 1168-1175
29. Brisson M., and Edmunds W.J. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 70 (2003) S9-S14
30. de Melker H., Berbers G., Hahne S., Rumke H., van den Hof S., de Wit A., et al. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 24 18 (2006) 3946-3952
31. Dworkin R.H., and Schmader K. The treatment and prevention of postherpetic neuralgia. Clin Infect Dis 36 (2003) 877-882
32. Koplan J.P., and Harpaz R. Shingles Vaccine: Effective and costly or cost-effective. Ann Intern Med 145 5 (2006) 386-387
33. World Health Organization. Choosing interventions that are cost-effective. Table: threshold values for intervention cost-effectiveness by region. Accessed at www.who.int/choice/costs/DER_levels/en/index.html, September 11, 2006.
34. U.S. Department of Labor Bureau of Labor Statistics. Comparative Real Gross Domestic Product Per Capita and Per Employed Person: Fifteen Countries 1960-2005. June 2006.
35. Neumann P., Rosen A.B., and Weinstein M.C. Medicare and cost-effectiveness analysis. N Engl J Med 353 October (14) (2005) 1516-1522
36. Turner D.A., Wailoo A.J., Cooper N.J., Sutton A.J., Abrams K.R., and Nicholson K.G. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine 24 (2006) 1035-1043
37. Maciosek M.V., Coffield A.B., Edwards N.M., Flottemesch T.J., Goodman M.J., and Solberg L.I. Priorities among effective clinical preventive services. Results of a systematic review and analysis. Am J Prev Med 31 1 (2006) 90-96
38. Hope-Simpson R.E. Postherpetic neuralgia. J R Coll Gen Pract 25 (1975) 571-575
39. Brisson M., and Edmunds W.J. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 88 (2003) 862-869
40. White R.R., Singhal P.K., Insinga R.P., Itzler R.F., Pellissier J.M., and Segraves A.W. Annual healthcare cost of herpes zoster (shingles) and its complications. International Society for Infectious Diseases 12th International Congress. June (2006)